Radiopharmaceuticals May Be Eligible For ASP Reimbursement Under CMS Proposal
This article was originally published in The Pink Sheet Daily
Executive Summary
Two key drugs likely to be affected by such a change are Cell Therapeutics’ Zevalin and GlaxoSmithKline’s Bexxar.